SRS16-86

SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].

Product Specifications

CAS Number

[1793052-96-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/srs16-86.html

Purity

98.0

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C(C1=CC(/N=C\C2=CN=CN=C2)=C(C=C1)NC3(C[C@H](C4)C5)C[C@H]5C[C@H]4C3)OC(C)(C)C

Molecular Formula

C26H32N4O2

Molecular Weight

432.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59 (5) :2041-53.|[2]Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111 (47) :16836-41.|[3]Yan Zhang, et al. Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res. 2019 Mar 1;1706:48-57.